Cantor Fitzgerald Comments on Korro Bio FY2025 Earnings

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Korro Bio in a report released on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings of ($8.91) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share.

Several other equities analysts have also recently issued reports on KRRO. Chardan Capital began coverage on shares of Korro Bio in a research note on Wednesday, April 16th. They issued a "buy" rating and a $25.00 price objective on the stock. Oppenheimer initiated coverage on Korro Bio in a report on Friday, January 10th. They issued an "outperform" rating and a $155.00 price target on the stock. Royal Bank of Canada reduced their price objective on Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a research note on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $115.00 target price on shares of Korro Bio in a research report on Thursday, March 20th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $114.63.

Korro Bio Trading Up 13.8 %

KRRO stock traded up $2.53 during trading hours on Thursday, hitting $20.93. 115,223 shares of the stock traded hands, compared to its average volume of 97,107. The stock has a 50-day simple moving average of $18.64 and a 200 day simple moving average of $36.38. The company has a market cap of $196.55 million, a P/E ratio of -2.23 and a beta of 2.66. Korro Bio has a one year low of $11.13 and a one year high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, topping analysts' consensus estimates of ($2.33) by $0.07. The firm had revenue of $2.27 million during the quarter.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in shares of Korro Bio by 374.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 12,391 shares of the company's stock valued at $414,000 after purchasing an additional 9,782 shares during the period. Rhumbline Advisers lifted its position in Korro Bio by 7.8% in the 4th quarter. Rhumbline Advisers now owns 9,602 shares of the company's stock worth $366,000 after buying an additional 691 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Korro Bio by 11.5% during the 4th quarter. Wellington Management Group LLP now owns 14,553 shares of the company's stock valued at $554,000 after buying an additional 1,501 shares during the period. Legal & General Group Plc grew its holdings in shares of Korro Bio by 664.1% during the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock valued at $165,000 after acquiring an additional 3,759 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Korro Bio in the fourth quarter worth $53,000. 13.18% of the stock is owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).